 |
 |
 |
 |
 |
 |
 |
 |
More JournalViews >>
NEW! Primary Drug Resistance and Strategies for First-Line HIV Treatment
Antiretroviral Strategy Update: Highlights From the XVII International AIDS Conference
African Americans and HIV: New Developments in Clinical Management
HIV specialists answer questions on:
Gene Copello, 1959-2008: AIDS Community Mourns Passing of Pioneering Washington, D.C. Advocate
HIV Drug Resistance Spreading in China, Researcher Says
Panel Discusses How Asian Migrant Women Are Vulnerable to HIV
35% of Annual New HIV Infections in Spain Occur Among Immigrants, Researcher Says at Conference
From the XVII International AIDS Conference:
- New SMART Study Analysis Appears to Confirm Link Between Abacavir and Heart Attack Risk
- Making HIV Testing Part of Emergency Care at St. Vincent's Hospital in New York City
- More Patients With High Viral Loads Experience Virologic Failure When Starting Therapy With an Abacavir-Based Regimen Than a Tenofovir-Based Regimen
- TMC278 Nanosuspension Long-Acting, Well-Tolerated in Early Test
- Full Coverage of AIDS 2008
HIV and Me: A Woman's Guide to Living With HIV
Free patient education! This easy-to-read guide from our sister site, TheBody.com, is now available to download or in print.
New SMART Study Analysis Appears to Confirm Link Between Abacavir and Heart Attack Risk for Some Patients
Jens Lundgren, M.D., explains the findings from a SMART study analysis confirming D:A:D results linking abacavir use to an increased risk for myocardial infarction in high-risk patients.
More Patients With High Viral Loads Experience Virologic Failure When Starting Therapy With an Abacavir-Based Regimen Than a Tenofovir-Based Regimen
Paul Sax, M.D., reviews one of the most important studies presented at AIDS 2008 showing that more patients with high viral loads experience virologic failure when starting therapy with an abacavir-based regimen than a tenofovir-based regimen.
"When to Start?" Has a New Answer
Joel Gallant, M.D., summarizes the latest changes to U.S. HIV treatment guidelines.
Analysis: U.S. Approval of Etravirine
Cal Cohen, M.D., M.S. summarizes the essential details of the approval of etravirine (TMC125, Intelence) and its impact.
Introducing Raltegravir
David Wohl, M.D., discusses the approval of raltegravir (MK-0518, Isentress) and its impact.
The Body PRO is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body PRO and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body PRO's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body PRO is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body PRO should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
© 2007 Body Health Resources Corporation